π¬ Third death in China's CAR-T trials
A third fatality has been reported from China's ongoing CAR-T trials, marking a significant concern in the medical community. The deaths occurred within the scope of these trials being conducted in China. Specific figures and dates for these incidents were not disclosed in the report. These opaque trials are under scrutiny due to the lack of transparency surrounding adverse events. Further updates are awaited from the regulatory bodies overseeing the research. π¬